(Q38055491)

27 August 2017

title

Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia (English)

1 reference

27 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

Gunhild Keller-V Amsberg

series ordinal

1

1 reference

27 August 2017

Tim H Brümmendorf

series ordinal

2

1 reference

27 August 2017

publication date

1 September 2012

1 reference

Expert Review of Anticancer Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

1121-1127

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

27 August 2017

cites work

1 reference

Practical management of patients with chronic myeloid leukemia receiving imatinib

21 January 2018

1 reference

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

21 January 2018

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity

21 January 2018

1 reference

Exploitation of the 3-quinolinecarbonitrile template for SRC tyrosine kinase inhibitors

21 January 2018

1 reference

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain

21 January 2018

1 reference

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

Cellular functions regulated by Src family kinases

21 January 2018

1 reference

Src family kinases in tumor progression and metastasis

21 January 2018

1 reference

SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy

21 January 2018

1 reference

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia

21 January 2018

1 reference

Abl tyrosine protein kinase

21 January 2018

1 reference

Nuclear tyrosine kinases: from Abl to WEE1.

21 January 2018

1 reference

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

21 January 2018

1 reference

Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.

21 January 2018

1 reference

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

21 January 2018

1 reference

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

21 January 2018

1 reference

Inhibitory effect of imatinib on normal progenitor cells in vitro

21 January 2018

1 reference

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

21 January 2018

1 reference

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.

21 January 2018

1 reference

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

21 January 2018

1 reference

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

21 January 2018

1 reference

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.

21 January 2018

1 reference

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

21 January 2018

1 reference

Homoharringtonine for the treatment of chronic myelogenous leukemia

21 January 2018

1 reference

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

21 January 2018

1 reference

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.12.84

1 reference

27 August 2017

1 reference